All In Biotech

Drug Trial Radar · NCT07368608

A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol(LDL-C)

A Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated LDL-C

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Nov 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
BeBetter Med IncIndustry
Sponsor type
Industry
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I/II clinical trial is designed to evaluate, through a single-dose Phase I segment and a multiple-dose Phase II segment, the safety/tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) characteristics of BEBT-701 administered by subcutaneous injection in patients with mild to moderate hypertension and elevated LDL-C , and to explore its preliminary efficacy.

Conditions

  • Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol

Interventions

  • BEBT-701 InjectionDrug

    Phase I: The starting dose of BEBT-701 injection is 100 mg; the single subcutaneous doses are 100 mg, 200 mg, 400 mg, 800 mg, and 1200 mg. Phase II: Based on the preliminary Phase I findings, three dose levels will be selected for the Phase II study, with BEBT-701 injection administered subcutaneously on Day 1 and Day 85.

  • BEBT-701 Injection Placebo(0.9% Sodium Chloride Injection)Drug

    Phase I:BEBT-701 injection placebo, administered as a single subcutaneous dose. Phase II:BEBT-701 injection placebo administered subcutaneously on Day 1 and Day 85.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Adverse Events (AEs)Time frame: Up to 36 months
  2. Low-Density Lipoprotein Cholesterol(LDL-C)Time frame: Up to 24 weeks
  3. 24hour-Ambulatory Blood Pressure Monitoring(24h-ABPM)Time frame: Up to 24weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.